MDNCOTCSurgical & Medical Instruments & ApparatusFiscal year ends February 28
Medinotec Inc.
Financials through Q2 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026
$5.00+0.00 (0.00%)
Close on Oct 16, 2026
- Market cap
- $58.78M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2022 to 2026
Gross margin
52.7%
Operating margin
11.2%
Net margin
8.2%
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +6.8% | +113.5% | – | – | |
| Gross profit | +6.4% | +106.6% | – | – | |
| Operating income | -65.7% | – | – | – | |
| Net income | -63.2% | – | – | – | |
| Free cash flow | +14.8% | – | – | – |
Returns and balance sheet
5 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2022 | FY2022 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 15.9% | |
| Return on assets | – | – | 11.7% | |
| Current ratio | – | – | 5.83 | |
| Debt to equity | – | – | 0.00 | |
| Net debt to EBITDA | – | – | -2.35× | |
| Interest coverage | – | – | 12.5× | |
| Capex to revenue | – | – | 0.0% |
Cash use needs five years of cash flow figures
Medinotec does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.2%
×Asset turnover1.43×
×Equity multiplier1.36×
=Return on equity, FY202615.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 8.2% | 1.43× | 1.36× | 15.9% |
| FY2025 | 23.7% | 1.57× | 1.80× | 67.1% |
| FY2024 | -8.1% | 1.08× | 1.97× | -17.1% |
| FY2023 | -35.3% | 0.34× | 2.79× | -33.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
5of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero$794.50K
- Cash generatingOperating cash flow above zero$906.80K
- Return on assets improvedROA up on the prior year44.9% → 11.7%
- Earnings backed by cashOperating cash flow above net income$906.80K vs $794.50K
- Less leverageLong-term debt to assets fell13.8% → 0.0%
- Better liquidityCurrent ratio rose4.27 → 5.83
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year52.87% → 52.71%
- More efficientAsset turnover rose1.90 → 1.43